Fatty Liver (MASLD) and GH-Axis Peptides: What Tesamorelin Research Shows About Liver Fat

Metabolic dysfunction-associated steatotic liver disease is common in the Gulf, and growth hormone signalling appears to influence how the liver stores fat. Trial data on tesamorelin offer a cautious, evidence-led view of what GH-axis peptides may and may not do.

By UAE Peptide Clinic Research Desk

Metabolic dysfunction-associated steatotic liver disease, or MASLD (previously called non-alcoholic fatty liver disease), is now among the most common chronic liver conditions worldwide. Regional surveys suggest the Gulf carries a particularly high burden, driven by central adiposity, insulin resistance and sedentary working patterns. Because the liver is also a major site of growth hormone action, clinicians and researchers have asked whether the GH axis plays a part in how fat accumulates there, and whether peptides that act on that axis could be relevant.

The GH axis and the liver

Growth hormone regulates lipid metabolism in several tissues. In the liver, it influences how fatty acids are taken up, stored and exported, and it stimulates production of IGF-1, which circulates back to affect insulin sensitivity. Observational research consistently links lower GH secretion with greater visceral fat and a higher likelihood of hepatic fat accumulation. Adults with GH deficiency, for example, show higher rates of steatosis, and studies suggest replacement can reduce liver fat in that group.

Visceral fat matters here because it drains directly towards the liver through the portal circulation, delivering free fatty acids and inflammatory signals. Reduced GH pulsatility with age, sometimes called somatopause, tends to coincide with exactly this pattern of visceral fat gain.

Research suggests that liver fat and visceral fat tend to move together, which is why GH-axis signalling is of interest in MASLD.

What the tesamorelin trials show

Tesamorelin is a GHRH analogue approved in the United States for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is the GH-axis peptide with the most robust controlled data on liver outcomes, although that evidence comes from a specific population rather than the general public.

• In a randomised, placebo-controlled trial in people with HIV and hepatic steatosis, published in JAMA in 2019, tesamorelin over 12 months was associated with a meaningful reduction in liver fat fraction measured by MRI spectroscopy compared with placebo.
• In the same trial, fewer participants on tesamorelin showed progression of fibrosis on biopsy, although the sample was small and the finding needs replication.
• Earlier phase 3 work showed reductions in visceral adipose tissue, which is the likely route by which liver fat falls.
• Trials in people without HIV are limited, and data in otherwise healthy adults with MASLD remain preliminary.

These findings are encouraging but should be read carefully. The studies enrolled a defined clinical population, effects on liver fat were not always sustained after treatment stopped, and tesamorelin is not approved or licensed as a treatment for MASLD.

Where other secretagogues fit

Ipamorelin, CJC-1295 and sermorelin act on the same axis through related mechanisms, and some clinicians use them in metabolic protocols. However, there are no comparable randomised trials examining liver fat outcomes for these peptides. Any suggestion that they behave like tesamorelin in the liver is extrapolation from mechanism and from the visceral fat literature, not demonstrated fact.

Clinical nuance: screening comes first

GH-axis peptides raise IGF-1 and can alter glucose handling, so they are not a substitute for the foundations of MASLD management: weight reduction, resistance and aerobic exercise, dietary change, and treatment of diabetes, lipids and blood pressure. Physician review typically begins with liver enzymes, fasting glucose and insulin, HbA1c, a lipid panel and IGF-1, and may include ultrasound or elastography to assess fibrosis. Anyone with advanced fibrosis, a history of liver cancer or other active malignancy, or unexplained abnormal liver tests needs specialist assessment before any GH-axis protocol is considered. Alcohol intake and interacting medicines also need to be reviewed.

If you're exploring liver and metabolic health as part of your protocol, our clinical team can review your case — take the 2-minute quiz at /find-my-stack or book a free consultation at /book.